Global PD-L1 Biomarker Testing Competitive Landscape Professional Research Report 2024
Research Summary
PD-L1 (Programmed Cell Death Ligand 1) biomarker testing is a diagnostic procedure used in oncology to determine the level of PD-L1 protein expression on the surface of cancer cells. It plays a crucial role in the field of cancer immunotherapy, particularly in the treatment of solid tumors with immune checkpoint inhibitors. The test involves analyzing tissue samples from a patient's tumor to assess the presence and degree of PD-L1 expression. The results of PD-L1 biomarker testing help oncologists and clinicians predict the patient's potential response to immunotherapies that target the PD-1/PD-L1 pathway. Higher PD-L1 expression is often associated with a better response to these treatments, making it a valuable tool in personalized cancer care by guiding treatment decisions and improving the effectiveness of immunotherapy for patients with certain types of cancer.
According to DIResearch's in-depth investigation and research, the global PD-L1 Biomarker Testing market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.
The major global manufacturers of PD-L1 Biomarker Testing include Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.
This report studies the market size, price trends and future development prospects of PD-L1 Biomarker Testing. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global PD-L1 Biomarker Testing market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the PD-L1 Biomarker Testing market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of PD-L1 Biomarker Testing industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of PD-L1 Biomarker Testing Include:
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
PD-L1 Biomarker Testing Product Segment Include:
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Others
PD-L1 Biomarker Testing Product Application Include:
Hospital
Diagnostic Center
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global PD-L1 Biomarker Testing Industry PESTEL Analysis
Chapter 3: Global PD-L1 Biomarker Testing Industry Porter’s Five Forces Analysis
Chapter 4: Global PD-L1 Biomarker Testing Major Regional Market Size and Forecast Analysis
Chapter 5: Global PD-L1 Biomarker Testing Market Size and Forecast by Type and Application Analysis
Chapter 6: North America PD-L1 Biomarker Testing Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe PD-L1 Biomarker Testing Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China PD-L1 Biomarker Testing Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) PD-L1 Biomarker Testing Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America PD-L1 Biomarker Testing Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa PD-L1 Biomarker Testing Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global PD-L1 Biomarker Testing Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources